https://www.selleckchem.com/pr....oducts/sbi-0206965.h
842 and 0.832 in the discovery and test sets, respectively. Overall survival (OS) after first DBF was significantly different between the CR-predicted BMV-L and BMV-H groups (median OS 26.7 vs 13.0 months, = .016). Among patients with a diagnosis-specific graded prognostic assessment of 1.5-2 or 2.5-4, the median OS after initial SRS was 33.8 and 67.8 months for CR-predicted BMV-L, compared to 13.5 and 31.0 months for CR-predicted BMV-H ( .001 and .001), respectively. Our CR model provides a novel approach showing good perfo
Like
Comment
Share
